To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.

Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF and site-specific conjugation platform XpressCF+ led to the discovery of STRO-001 and STRO-002, the company's first two internally-developed ADCs.